PH1S082 - Fundamentals of Pharmaceutical Manufacturing Technologies 01 Jan 2022 - 31 Aug 2028 | Version 1

Associated Module Information

Module Code: PH1S082
Module Title: Fundamentals of Pharmaceutical Manufacturing Technologies
Faculty: Faculty of Computing, Engineering and Science
Faculty Group: Chemical and Environmental Sciences
Faculty Sub Group: Chemical and Environmental Sciences
Module Leader: Suzanna Kean
Module Team:
First Intended Intake: APR 2022 Final Year of Intake:
Date Closed: 01 Jan 2022
Credit Value: 20 Credit Level: 4
Language: English
Percentage of Module Taught in Welsh: 0
Equivalent Module:
HECOS codes: 100144 - pharmaceutical engineering
HECOS Code Weighting: 100

Document Version Information

Version 1
Valid From 01 Jan 2022
Valid To 31 Aug 2028

Module Aims

The aim of this module is to give students a broad understanding of what current good manufacturing practices (cGMP) apply to the manufacture of medicinal products, and how this relates to validation. It will consider industry standard guidelines and best practices for manufacturing safe and effective medicines for the public. The course is based on the principles of quality by design, risk management and continuous improvements as per the ICH (International Conference on Harmonisation) guidelines Q8, Q9 and Q10.

Content Summary

Indicative Syllabus:

• Introduction to the manufacture of medicinal products

• The need for current Good Manufacturing Practices (cGMP)

• Validation life-cycle

• ISPE Baseline Guide 5 (Commissioning and Qualification)

• Good Automated Manufacturing Practices (GAMP 5)

• Manufacturing technologies for finished pharmaceuticals, active pharmaceutical ingredients (API), biopharmaceuticals and medical devices

• Cleaning validation

• Introduction to Risk management tools

• Harmonized regulatory compliance

This module is delivered through open/distance learning resource packs, pre-recorded lectures, problem-solving exercises and case studies.

Learning and Teaching Methods

Activity Type Hours
Independent Study 100
Directed Study 64
Formative Assessment - Independent 36
Total Hours Selected 200

Learning Outcomes

# Learning Outcome
LO1 Determine what cGMPs apply to the manufacture of medicinal products in various countries in accordance with regional regulatory expectations and identify the similarities and differences for the manufacture of active pharmaceutical ingredients (API), biopharmaceuticals, and medical devices
LO2 Apply the industry standard guidelines, including ISPE Baseline Guide 5 for Commissioning and Qualification‘, and GAMP5 (Good Automated Manufacturing Practice) to Commissioning and Qualification exercises and define what equipment systems require commissioning and what systems should be qualified in the context of new manufacturing processes.
LO3 Apply a range of risk-management tools in making regulatory based decisions

Module Requisites

N/A

Assessment Criteria

Assessment Category Assessment Type Description Duration Word Count Weight (%) Best of? Pass Mark
Asynchronous Assessment Report 2 Series of Short Questions 0 1200 30 No 40
Asynchronous Assessment Report 1 Assignment on Application of GMPs in Industry 0 3000 70 No 40

Assessment Matrix

Assessment Type Learning Outcomes
LO1 LO2 LO3
Report 2
Report 1

Reading List

Open distance/learning pack of materials resources

Supplemental Reading:

• International Conference on Harmonisation (ICH) guidelines Q8, Q9, Q10, Q11

United States code of federal regulations online (www.fda.gov)

EU cGMPs Eudralex collection online ( http://pharmacos.eudra.org/F2/eudralex/vol-4/home.htm )

Pharmaceutical Inspection Convention / Co-operation Scheme (PIC/S) suite of regulatory guidelines and recommendations online (www.picscheme.org)

ISPE Baseline Guide 5 (Commissioning and Qualification);

ISPE Good Automated Manufacturing Practice (GAMP5)